dennis mccain
  • Home
  • Investing
    • Dividend Kings
    • Div Aristocrats
    • Div Champions
    • Business Dev Cos
    • Monthly Dividends
  • Options
    • Weekly Options

Investing

Ideas and Strategies on Investing.

Previous Articles

Celgene

2/13/2017

1 Comment

 
This just may be a great time to begin accumulating shares of Celgene Corporation. This company has been in an overall uptrend for the last fifteen years and technicians are seeing something that may be signaling that the shares are about to move higher. Shares rose from 2003 thru 2007 before hitting resistance near $40 per share. At that point the stock moved sideways for the next six years as it struggled to break above that $40 resistance.

In 2013 the stock broke out again and moved higher. As it approached $130 per share the stock once again hit resistance and pulled back. It has now been moving sideways for two years and is approaching a technical uptrend line (see below). You can almost see a pennant forming forcing the shares more and more toward $130. 

From a purely technical view, as these shares move higher thru the $130 per share level, the shares could see a significant move higher. Shares could easily double within a year of the breakout and triple over a couple of years.

And that would be an incredible move! 


Picture
Celgene Corporation Monthly Chart

​Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID to treat multiple myeloma; and OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, ankylosing spondylitis, Behcet's disease, atopic dermatitis, and ulcerative colitis. The company's products also include VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); THALOMID for the patients with multiple myeloma and erythema nodosum leprosum; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN products. Its clinical stage products include OTEZLA for the treatment of various immune-inflammatory diseases; sotatercept for the treatment of renal anemia, beta-thalassemia and MDS; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; PDA-002 for the treat diabetic foot ulcers and peripheral neuropathy; and PNK-007 for hematological malignancies treatment. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; TriNetX, Inc.; Triphase Accelerator Corporation; Nurix Inc.; Abbott; Sage Bionetworks; and PharmAkea Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.
(Summary) (Company) (Chart)
11 February 2016
Price $115.61
1yr Target $141.22
Analysts 23
Dividend ---
Payout Ratio ---

1yr Cap Gain 22.15%
Yield ---
1yr Tot Return 22.15%

P/E 46.50
PEG 2.07
Beta 1.79


EPS (ttm) $2.49
EPS next yr $8.71
Forward P/E 13.28
EPS next 5yr 22.44%
1yr Price Support $195.45

Market Cap $89.54 Bil
Revenues $11.23 Bil
Earnings $2.00 Bil
Profit Margin 17.80%

Quick Ratio ---
Current Ratio ---
Debt/Equity ---


1yr RevGR 21.31%
3yr RevGR 19.81%
5yr RevGR 18.32%

1yr EarnGR 28.35%
3yr EarnGR 13.86%
5yr EarnGR 11.80%

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA ---
ROE ---


Picture
1 Comment
cara mengatasi kulit kepala gatal, berkerak dan mengelupas seperti ketombe link
11/5/2018 12:18:35 am

Good information, thank u and please visit back my article~!

Reply



Leave a Reply.

    Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

    Picture

    Author

    I am an Individual Investor with specific interest in long term growth and then enhancing my returns with income from dividends and derivatives. I don't recommend stocks to anyone (it's a good way to lose friends) and no one reading this should misinterpret my blog as a recommendation for any type of investment. I am writing this solely for myself and my kids.


    RSS Feed


    Picture
    Top 100 Blogs for Dividend Investors

    Picture
    Follow Me on StockTwits!



    Dividend Growth Stocks
    Dividend Growth Investor


    Picture
    I'm on Seeking Alpha too!

    Archives

    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013


    ADDITIONAL RESOURCES:
    4 Month INDU Chart
    Dividend Ex-Dates
    Bidness Etc
    SharpCharts Voyeur
    StockCharts.com

    FINVIZ
    Seeking Alpha
    BDC Reporter
    Roadmap2Retire
    DivHut
    Dividend Growth Investor

    Dividend Yield

    Stock Market Mentor
    Chart Swing Trader
    Dividend Announcements
    IBD TV
    Stocks to Watch Today
    Dividend Detective

    DISCLAIMER
     I am not a licensed investment adviser, and I am not providing investment advise for you on this site. Please consult with an investment professional before you invest your money. Any opinion expressed here should not be treated as investment advice. I am not liable for any losses suffered by any party because of data or information published on this blog. Past performance is not a guarantee of future performance. Unless your investments are FDIC insured, they may decline in value.

    Picture
Powered by Create your own unique website with customizable templates.